Diversified Consumer Services
Company Overview of University of Manchester
University of Manchester is an educational institution that provides undergraduate, graduate, and postgraduate programs. It offers courses in accounting and finance; aerospace engineering; anatomical science; cognitive neuroscience and psychology; computer science; economics; learning disability; modern languages and cultures; and psychology. University of Manchester was formerly known as Victoria University of Manchester and changed its name to University of Manchester in March, 2003. The university was founded in 1824 and is based in Manchester, United Kingdom.
Manchester, M13 9PL
Founded in 1824
Key Executives for University of Manchester
President and Vice-Chancellor
Director of Manchester Interdisciplinary Biocentre
Compensation as of Fiscal Year 2015.
University of Manchester Key Developments
AstraZeneca and The University of Manchester Announce Collaboration
Sep 8 15
AstraZeneca and The University of Manchester announced a collaboration harnessing clinical bioinformatics to deliver personalized healthcare for cancer patients. The five-year agreement will see the organizations apply clinical trial bioinformatics to better identify the right cancer treatment for the right patient at the right time. As part of the collaboration, AstraZeneca will provide a total of £11.5 million to support clinical bioinformatics research led by a dedicated team of investigators within the recently established Centre for Cancer Biomarker Sciences at the Manchester Cancer Research Centre. The research will be carried out in partnership with the clinical trials unit of The Christie NHS Foundation Trust, which is at the forefront of experimental cancer medicine in the UK. Projects will include the development of a new bioinformatics system to capture and integrate clinical trial safety, efficacy, biomarker and drug distribution data in real time, presenting the information in the form of graphs that can be easily interpreted by clinicians to help tailor the treatment for patients. The collaboration will also support new training programmes in clinical research and pharmacokinetic and pharmacodynamic modeling for investigators to understand the distribution and clinical effects of medicines within the body. This collaboration builds on existing scientific collaborations between AstraZeneca and The University of Manchester, ranging from research into novel cancer medicines to progressing treatments for lung cancer, advancing inflammatory research and developing new drug delivery systems.
The University of Manchester Signs Collaboration Agreement with Abcodia for Early Detection of Lung Cancer
Aug 6 15
The University of Manchester has signed a collaboration agreement with Abcodia to perform proteomics studies on a cohort of non-small cell lung cancer cases from the UKCTOCS biobank, with the aim of discovering new blood-based biomarkers for earlier detection of the disease. The group at Manchester, led by Professor Tony Whetton, Professor of Cancer Cell Biology and Director of the Stoller Biomarker Discovery Centre and the Manchester Precision Medicine Institute, plus Dr. Phil Crosbie, Consultant in Respiratory Medicine at the Northwest Lung Centre and senior clinical lecturer at The University of Manchester, will utilise longitudinal pre-diagnosis serum samples from the UKCTOCS biobank to find markers that elevate early, before clinical presentation with symptoms.
Basilea Pharma Inks License Agreement for Novel panRAF Kinase Inhibitors
Apr 1 15
Basilea Pharma announced that it has entered into a license agreement for novel panRAF kinase inhibitors with a consortium of organizations including The Institute of Cancer Research, London, Cancer Research Technology, the Wellcome Trust and The University of Manchester. The agreement grants Basilea exclusive global rights to develop, manufacture and commercialize novel panRAF kinase inhibitors which originate from research at The Institute of Cancer Research by scientists funded by Cancer Research UK and the Wellcome Trust. RAF kinases play an important role in tumor cell proliferation. The oral, small molecule panRAF inhibitors target BRAF and other growth pathways relied upon by resistant tumor cells. The consortium will lead clinical phase 1 development for the lead compound. Basilea will assume full operational responsibility thereafter. The consortium receives an upfront payment and is eligible to potential milestone payments on achievement of pre-specified clinical, regulatory and commercial milestones, as well as tiered royalties on future net sales.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|